Cloperastina Normon is used in areas where short-term symptom management is appropriate for symptoms related to physical discomfort. The medicine is commonly used to help with the dry, irritative, and non-productive cough and may be applied in conditions associated with acute or disruptive episodes, such as common respiratory infections.

Quick Fact: Irritative Cough Symptoms

Focus	Description
Symptom Type	Dry, persistent, and non-productive cough
Primary Benefit	Contributes to easing the overall symptom load, supports comfort
Use Scenario	When cough may interfere with daily function or sleep
Target Group	Adult and pediatric patients

This medication is relevant for easing symptom clusters that may become intense or disruptive, specifically targeting the cough that is unproductive. It is commonly used to help with symptoms that cluster into patterns requiring supportive management, including cough associated with respiratory illnesses, tracheitis, and bronchitis.

“The medicine plays a role in managing persistent, dry coughing spells that interfere with a patient’s well-being.”

It assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms, supporting the patient, especially when symptoms become momentarily overwhelming during the night-time. This symptomatic support is relevant for both adult and pediatric patients.

Cloperastina Normon is an antitussive medication primarily indicated for the symptomatic treatment of unproductive coughs (dry, irritative, or nervous coughs) in adults and children from 2 years of age and older.

---

Contraindications (Who Should NOT Use It)

This medication is strictly contraindicated in several situations to prevent serious adverse effects or complications:

• Hypersensitivity: Individuals with a known allergy or hypersensitivity to cloperastine, to other antihistamines, or to any of the product's inactive ingredients.
• Pregnancy and Breastfeeding: Use is contraindicated during both pregnancy and lactation, as safety has not been fully established.
• Age: Children under 2 years of age must not take this medicine.
• Concurrent Medications: It should not be used in patients taking Monoamine Oxidase Inhibitors (MAOIs), a class of antidepressant drugs. Concurrent use with expectorants or mucolytics is also contraindicated, as this can lead to a potentially dangerous buildup of mucus and phlegm in the respiratory tract.

---

Precautions (Use with Caution)

Consult a healthcare professional before using Cloperastina Normon if you have certain pre-existing conditions, as the drug's properties may exacerbate them:

• Eye Conditions: Patients with ocular hypertension or glaucoma (particularly angle-closure glaucoma).
• Prostate: Men with prostatic hypertrophy (enlarged prostate).
• Respiratory Conditions: Individuals with asthmatic cough, productive cough, or respiratory failure.

Cloperastina Normon Interactions with other medicines and products

Interaction Domain	Affected Substance Category	Official Restriction/Outcome
Pharmacodynamic	Central Nervous System (CNS) Depressants (e.g., Anxiolytics, Hypnotics, Narcotics, Sedatives)	Enhanced sedative effect (potentiation of drowsiness).
Contraindication	Monoamine Oxidase Inhibitors (MAOIs)	Concomitant use is Contraindicated due to risk of serious interaction.
Pharmacodynamic	Alcohol (Ethanol)	Enhanced sedative effect; co-administration is officially avoided.
Pharmacodynamic	Anticholinergic Drugs (e.g., Tricyclic Antidepressants)	Reciprocal increase of anticholinergic side effects.
Pharmacokinetic	Phenytoin	May inhibit the hepatic metabolism, potentially leading to increased exposure of Phenytoin.

---

The regulatory profile for Cloperastine (fendizoate salt) details specific drug-substance and drug-drug interaction patterns based on its pharmacological properties. The most significant restriction is the formal contraindication against co-administration with Monoamine Oxidase Inhibitors (MAOIs).

A primary interaction pattern is the potentiation of effects when combined with other agents that act on the central nervous system. Co-administration with CNS Depressants, including certain anxiolytics and hypnotics, is documented to enhance the sedative effect and increase drowsiness. For the same reason, the official label advises that co-administration with Alcohol must be avoided.

Furthermore, because Cloperastine possesses inherent anticholinergic activity, co-use with other Anticholinergic Drugs can lead to a reciprocal increase in shared effects. The regulatory information also includes a pharmacokinetic interaction, noting that Cloperastine may inhibit the metabolism of certain co-administered drugs like Phenytoin, resulting in the potential for increased plasma concentrations of Phenytoin. No mandatory timing-separation rules or significant food interactions are documented in the official labeling.

Central Inhibition of the Cough Threshold

The primary mechanism involves the interaction of Cloperastine with the Sigma-1 (sigma1) receptor and GIRK channels (G protein-coupled inwardly rectifying K^+ channels) within the brain's medulla oblongata. This molecular activity modulates central neuronal networks, leading to an elevation of the cough reflex threshold. This action fundamentally decreases the likelihood of excessive neural output from the cough center, constituting the core of the antitussive effect.

Attenuation of Peripheral Airway Input

A secondary mechanism involves the drug acting as an antagonist at the Histamine H1 receptor and, to a minor extent, muscarinic receptors. This action results in the attenuation of histamine-mediated effects and a reduction of sensory signal input to the central cough center. This physiological change complements the primary central inhibition.

Mechanism Constraint

The core inhibitory mechanism is inherently specific to inhibiting the reflex efferent signal. This mechanism is physiologically constrained when the cough reflex is required for the removal of biological material. This constraint limits the physiological utility of the mechanism to scenarios where the reflex serves no essential clearance function.

Administration and Dosing Guidelines

Cloperastina Normon is a medicine for oral administration only, typically presented as a liquid solution or syrup. The usage protocol focuses on precise volume measurement and specific timing, as the active substance is the cloperastine fendizoate salt.

Administration Scope

Feature	Usage Guidance
Route of Administration	Oral ingestion of the liquid solution.
Frequency Pattern	Three times a day (e.g., morning, midday, and night).
Timing in Relation to Meals	Dosing is advised to be administered before meals.
Preparation Requirements	The bottle must be shaken well before use to ensure the dose is consistent. The prescribed dose must be measured with a calibrated device.
Duration of Use	The medicine is intended for short-term symptomatic management only.

Labeled Dosing Regimens

The volume of the oral solution administered must be precisely adjusted based on the patient's age:

• Adults and Adolescents (12 years and older): The standard regimen is 10 ml per dose, taken three times daily. Standard guidelines may recommend a total daily dose of 30 ml, with some regional maximums reaching up to 60 ml or 80 ml in divided doses.
• Children (Ages 2 to 6 years): The dose is 2.5 ml per administration.
• Children (Ages 6 to 12 years): The dose is 5 ml per administration.

These parameters define a structured approach for using the medication, emphasizing the correct volume and timing, particularly the required adjustment of the dose for pediatric patients.

The Research Landscape for Cloperastine Fendizoate

Research examined the medicine in the context of its classification for cough. The regulatory evaluation is primarily based on clinical trials, including short-term, randomized, placebo-controlled studies (RCTs). These studies explored symptom changes and evaluated outcomes related to physical discomfort experienced during periods of heightened symptom activity. The evidence base for the specific racemic form of cloperastine has been evaluated against what is known and what remains uncertain, contributing to the overall evidence landscape for cough symptom patterns.

Evidence for Symptomatic Relief of Irritative Cough

Research examined the medicine for its use in the short-term evaluation of cough symptoms, particularly persistent, non-productive, or irritative cough. In these RCTs, the medicine was observed in a defined population against an inactive substance (placebo). Researchers monitored the evolution of symptoms in the observed populations, and findings describe patterns regarding cough frequency and severity. Further research monitored functional measures, such as the quality and duration of night rest/sleep. These patient-reported outcomes provide context about how patients reported their experience during acute episodes.

Studies in Specific Patient Groups

The medicine was evaluated in a variety of patient groups, including adult outpatients with chronic cough and those with cough following procedures like tracheostomy. Older clinical trials included pediatric patients (children). Research explored the use of the medicine in this younger population, primarily through clinical trials rather than extensive recent RCTs. Findings for this population were mixed in comparative research, indicating that results apply only to the populations studied and that certainty remains low for certain subgroups. Data for certain groups remain insufficient.

Consistency and Research Gaps

Evidence quality varies across studies, and some core evidence is derived from older clinical trials. A significant limitation is the heterogeneity of study populations, often mixing both dry and productive coughs. This lack of uniformity limits the interpretation of the evidence. Long-term effects are not fully established, and comparative evidence aligning with recent regulatory standards is also lacking in some areas.

Key Studies & References FICHA TECNICA CLOPERASTINA NORMON 3,54 mg/ml SUSPENSION ORAL (AEMPS SPC)

Common questions about Cloperastina Normon (FAQ)

Q: Does Cloperastina Normon interact with common cold or flu medications?

Official regulatory documents state that Cloperastina Normon is contraindicated for use with expectorants or mucolytic drugs. The purpose of Cloperastina is to inhibit the cough reflex, and combining it with medicines that increase mucus production is associated with a risk of an unsafe buildup of secretions in the airways.

Q: What happens if I take Cloperastina Normon too close to bedtime?

Official product information indicates that Cloperastina Normon has the potential to cause drowsiness as an adverse effect. Taking the medicine near bedtime may enhance this sedative effect, an effect noted in the product information.

Q: Can Cloperastina Normon cause or worsen stomach upset?

Official safety documents report that gastrointestinal issues, such as nausea and vomiting, are possible adverse effects of this medicine. These effects are generally classified as uncommon.

Q: Why do some people confuse Cloperastina Normon with allergy medication?

The active ingredient, cloperastine, has mild antihistaminic activity, which is a property it shares with many common allergy relief medications. This characteristic is the reason it is often grouped or discussed in similar contexts.

Q: How quickly can a person expect Cloperastina Normon to start working?

Studies and official information on cloperastine's absorption indicate that the onset of its antitussive action is generally rapid after oral administration. Onset is typically described as occurring within 20 to 60 minutes.

Q: How long do the effects of Cloperastina Normon usually last?

Regulatory documentation suggests that the therapeutic effects of a single dose of cloperastine last for a limited period. The duration of action is generally reported as approximately three to four hours.

Q: Can people with high blood pressure use Cloperastina Normon?

Official warnings state that due to the medicine's mild anticholinergic effects, the official product information notes that caution is advised in patients with pre-existing hypertension, or high blood pressure.

Q: Are there specific warnings for elderly patients using Cloperastina Normon?

Regulatory product information advises that while this medicine can be used by elderly patients, official documentation indicates that caution is advised during its use in this population.

Q: Is Cloperastina Normon available only by prescription, or is it over-the-counter?

In many countries, Cloperastina Normon is widely available as an over-the-counter (non-prescription) medicine. However, the legal dispensing status of the drug may vary based on local regional regulations.

Q: Does Cloperastina Normon contain any common allergens like gluten or lactose?

Official excipient lists for the oral suspension do not contain common allergens such as gluten or lactose. However, the formulation does include methyl and propyl parahydroxybenzoates, which regulatory documents note have the potential to cause allergic reactions, sometimes delayed.

Q: Are there official guidelines for stopping Cloperastina Normon after a cough is resolved?

Cloperastina Normon is officially indicated for short-term symptomatic treatment only. Official patient information suggests seeking consultation with a healthcare professional if symptoms worsen or do not show improvement after a few days of treatment.

How to Store and Dispose of Cloperastina Normon?

The storage and disposal of Cloperastina Normon oral solution must comply strictly with official regulatory guidelines to maintain product integrity and ensure safety.

Official Storage Requirements

The most critical requirement is to keep Cloperastina Normon out of the sight and reach of children at all times. To protect the oral solution, it must be stored in its original container and kept tightly closed. Patients must refer to the product packaging for the exact temperature and environmental conditions required, which commonly include protection from excessive light and humidity. The medicine must not be used past the expiration date printed on the label.

Official Disposal Requirements

Disposal must adhere to environmental safety mandates. It is explicitly required not to flush the medicine down the toilet or pour it into a drain. To safely dispose of any unused or expired product, individuals must consult a pharmacist or local waste management service for information on approved drug take-back programs.